Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Peer Review reports

Original Submission
23 Jun 2009	Submitted	Original manuscript
12 Aug 2009	Reviewed	Reviewer Report - PUJOL JEAN LOUIS
13 Oct 2009	Reviewed	Reviewer Report - Bernardo Goulart
18 Nov 2009	Author responded	Author comments - Yumiko Asukai
Resubmission - Version 2
18 Nov 2009	Submitted	Manuscript version 2
18 Nov 2009	Author responded	Author comments - Yumiko Asukai
Resubmission - Version 3
18 Nov 2009	Submitted	Manuscript version 3
11 Dec 2009	Reviewed	Reviewer Report - Bernardo Goulart
14 Jan 2010	Author responded	Author comments - Yumiko Asukai
Resubmission - Version 4
14 Jan 2010	Submitted	Manuscript version 4
18 Jan 2010	Author responded	Author comments - Yumiko Asukai
Resubmission - Version 5
18 Jan 2010	Submitted	Manuscript version 5
Resubmission - Version 6
	Submitted	Manuscript version 6
Resubmission - Version 7
	Submitted	Manuscript version 7
28 Jan 2010	Author responded	Author comments - Yumiko Asukai
Resubmission - Version 8
28 Jan 2010	Submitted	Manuscript version 8
Publishing
29 Jan 2010	Editorially accepted
29 Jan 2010	Article published	10.1186/1471-2407-10-26

Back to article page